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ABSTRACT (Maximum 200 words)
Sulfur mustard (HD) is a powerful blistering agent whose mechanism is poorly understood. One of the effects of this chemical warfare agent is to lower NAD* levels through the activation of poly (ADP-ribose) polymerase; HD also depletes ATP, the major energy supply for biochemical reactions within the cell. ATP is a biological marker that can be measured in HD-exposed cells by using a chemiluminescent reaction based on the luciferin-luciferase reaction. This assay is conveniently measured by the use of a luminometer and exhibits a reproducible linear standard curve. Three prototypic inhibitors of the poly (ADP-ribose) polymerase have been studied to determine their effect on restoring or maintaining ATP levels in HDexposed human peripheral blood lymphocytes (PBL). Two of the inhibitors, ICD 2250 (1 (2H)-isoquinolinone, 3,4-dihydro-5-[3-(methylamino)propxy]-monohydrochloride) and ICD 2163 (3,4-dihydro-5-methyl-l(2H)-isoquinolinone), are very effective in maintaining ATP levels in HD-exposed (200 uM) PBL. With both drugs, a concentration of 100 uM restores ATP levels to nearly those found in unexposed cells with both drugs. The third inhibitor, ICD 967 (niacinamide), is not nearly as effective. This assay is now under development to test ATP levels in human epidermal keratinocytes, a more relevant in vitro model for vesication.
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Materials and Methods
Reagents
Isolation of PBL:
Blood was obtained by venipuncture from volunteers under an approved human use protocol. The blood was diluted with a phosphate buffered saline (PBS) (0.003M KP0 4 , 0.15 M NaCL, 0.1M EDTA, pH 7.4) solution (5). Thirty-five mL of diluted blood was then layered on 10 mL of Percoll (d= 1.080). The density gradient was then centrifuged at 425 xg, for 30 minutes at 20° C. The lymphocyte bands were aspirated and pooled into 50 mL centrifuge tubes and washed with Tyrode's free buffer (3). The lymphocytes were then centrifuged at 250 xg for 12 minutes at 20°C. Cell pellets were resuspended in Tyrode's free buffer, combined into one centrifuge tube, washed again in Tyrode's free buffer and finally resuspended in RPMI1640 buffer. The cells were counted using trypan blue on a hemacytometer and their concentration was adjusted to 2 xlO 7 cells per mL.
Exposure of lymphocytes to sulfur mustard:
Lymphocytes were plated at lxlO 6 cells per well in a 96-well plate. The desired pretreatment compounds were added to the appropriate wells at concentrations ranging from 200 to 2000 uM. One-half of the plate represented control samples and samples containing buffer and pretreatment compound at designated concentrations. The other half of the plate represented lymphocyte samples to be exposed to 200 \xM HD and pretreatment compound at designated concentrations. A 10 mL stock (4000 piM) vial of HD was diluted 1:4 with RPMI 1640 to a working concentration of 1000 \iM, and 40 \ih of this solution was added to each well to give a final HD challenge dose of 200 uM. After samples had been exposed to HD, the plate remained in the surety hood for one hour to allow complete hydrolysis of HD and venting of volatile agent. The plate was then placed in the 5% CO2 incubator for an additional three hours until ATP levels could be measured.
Luminescent ATP assay:
ATP standard solution (10 u,M) is prepared by adding 10 mL of doubly distilled, deionized water to the vial of ATP supplied in the Bio Orbit ATP assay kit. After withdrawing enough ATP standard solution (1.0 mL) to perform a standard curve, the remaining reconstituted ATP standard is distributed into 1.0 mL aliquots in Eppendorf tubes and frozen at-20°C. 
ATP Standard
Results
A typical standard curve of ATP is shown below in Figure 1 . The curve was linear between 5 nM and 5 jiM ATP and is reproducible. The r 2 value was very consistent at the 0.99 level using this chemiluminescent assay. When various concentrations of HD were added to PBL, intracellular ATP levels decreased in a dose-dependent manner (Figure 2 ). This reduction appeared to be in two phases: a rapid initial ATP loss between 0 and 50 uM HD, and a slower decrease that seemed to reach an approximate maximum of 50% loss at 250 uM HD. When HD concentration was increased to 500 jxM, there was no further loss in ATP levels beyond that seen at 250 uM. The challenge dose of 200 \xM HD was used in subsequent experiments since it appears from data shown in Figure 2 that the maximum effect occurs at this dose.
Inhibitors of poly (ADP-ribose) polymerase were investigated to determine whether the ATP levels of lymphocytes would be spared or restored by the addition of these compounds to the cells before they were exposed to HD. Three prototypic compounds were selected from known inhibitors of this enzyme, and the results from these studies appear below. The poly ADP-ribose polymerase (PARP) inhibitor ICD 2250 (Fig. 3) was added to the cells immediately prior to HD exposure, and ATP levels were determined at 3 hr postexposure. ATP levels were protected at ICD 2250 concentrations of 100 \iM or greater. At ICD 2250 concentrations of 10 |jM and 30 [iM, there was incomplete but important protection of ATP levels, 34% and 71% ATP protection, respectively. ICD 2250 had no effect on control ATP levels in unexposed lymphocytes. 
Conclusions
A chemiluminescent assay has been developed for ATP levels in HD-exposed human peripheral blood lymphocytes. This assay was linear within the concentrations of 50 nM and 5 uM ATP, was very reproducible, and has a consistent r 2 . value of 0.99. The assay was easy to perform and can be learned in a short time by laboratory personnel.
ATP levels in PBL decrease in a dose-dependent manner when analyzed 3 hours after HD exposure. Two phases of ATP loss occur; a rapid initial phase between 0 and 50 uM HD and a slower loss at higher concentrations of HD up to 500 uM. This ATP loss appears to reach a plateau at approximately 50% and does not decline further with increasing HD concentration.
Breaks in DNA caused by alkylation activate the poly (ADP-ribose) polymerase that depletes the ATP levels in PBL. ATP loss and disruption of metabolic activity appears to be a very sensitive step in the injury and potential death of a cell following mustard exposure. Since ATP is involved in a myriad of metabolic activities, many critical biochemical pathways could be affected by this loss. Restoration of ATP levels and the resulting metabolic improvement may be helpful in reversing the cellular damage caused by this agent followed by recovery of the damaged cell.
With this goal in mind, we have investigated drugs that inhibit poly (ADP-ribose) polymerase. Three of the prototypic drugs that we investigated had varying effects on the ATP levels. ICD 967 showed a favorable effect only at very high levels.
However, ICD 2250 and ICD 2163 show beneficial effects in concentrations as low as 10 uM and approach ATP levels of unexposed cells when 100 uM concentration of drugs were used. Increasing the drug level to 300 or 1000 uM did not appear to have any extra advantage. The results of this study give some hope to finding a medical countermeasure for the vesicant agent HD. The in vitro findings in PBL will be further investigated in human epidermal keratinocytes, another in vitro model that appears to be a more relevant target of mustard exposure. If these ATP results can be confirmed in this model, the drugs will be passed on for further testing in an in vivo model currently available at this institute.
This assay was very accurate but had some technical aspects that must be considered. Temperature control was critical since the temperature optimum of the luciferinluciferase assay is 25°C. Early results were dependent on the position of the assay wells in the plate, since the assay was slowly denatured before completion of plate reading when the heating platform was at 37°C. The assay is now performed at room temperature using temperature-equilibrated reagents. We also noticed that splashing of the reagents was occurring inside the luminometer and may have been due to using reagents that were cold and not thoroughly dissolved. This problem was solved by pre-priming injector probes with room temperature reagents (25°C) and siliconizing the probe tips.
Another problem encountered was artifactual data results from a high background thought to be due to exogenous light activation. Wrapping the ATP Monitoring Reagent syringe in aluminum foil to preclude light activation solved the problem.
